Labeling: Label Error On Declared Strength; Some bottles of product were missing the color-coded strength on the primary display panel of the label.
Take action
Contact the company
📍Recalling firmUpsher Smith Laboratories, Inc.6701 Evenstad Drive · Maple Grove, MN 55369
✎ GovInfoNow plain-language explainer
Upsher-Smith Laboratories, Inc. is recalling a specific lot of Divalproex Sodium Delayed-Release Tablets, USP, 500 mg. The issue is that some bottles are missing the color-coded strength on the primary display panel of the label. This recall affects 11,316 bottles distributed nationwide and in Puerto Rico. Read more at govinfonow.com/recall/48452-upsher-smith-laboratories-inc-recalls-divalproex-sodium-delayed-release-tablets.
“Upsher-Smith Recalls Divalproex Sodium Tablets Due to Label Error.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48452-upsher-smith-laboratories-inc-recalls-divalproex-sodium-delayed-release-tablets. Based on FDA recall #D-127-2013 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-127-2013%22&limit=1).
The FDA announced on Dec. 10, 2012, that Upsher-Smith Laboratories voluntarily recalled Divalproex Sodium Delayed-Release Tablets due to labeling errors where the primary display panel lacked the color-coded strength. The agency classified the recall as Class III.
Some bottles were missing the color-coded strength on the primary display panel of the label. The recall involves 11,316 bottles distributed nationwide and in Puerto Rico.
Context
GovInfoNow's records show Upsher Smith Laboratories has had four other recalls since Nov. 20, 2012. Other recent recalls of similar products include American Regent Levocarnitine Injection Recall (April 16, 2026), Unichem Recalls Doxazosin 4mg Tablets Due to Wrong ID Imprint (Jan. 21, 2026), and American Health Packaging Buprenorphine Tablets Recall (Aug. 19, 2026).
How to tell if you have this one
Check your bottle for NDC 0245-0182-11 and Lot #310162 with an expiration date of 09/14. Verify if the primary display panel of the label is missing the color-coded strength indicator. The product contains 100-count tablets per bottle.
Brand
Upsher-Smith Laboratories
Category
Drug
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-127-2013 (December 10, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-127-2013 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.